1-20 of 136 Search Results for

ppi

Sort by
Book Chapter
Series: Genome Dynamics
Volume: 6
Published: 27 August 2009
10.1159/000235762
EISBN: 978-3-8055-9193-5
... Abstract Protein-protein interaction (PPI) studies are frequently used as a starting point for the functional annotations of unknown proteins according to the principle of ‘guilty by association’. Moreover, they deliver information for the understanding of specific virulence mechanisms. We...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350631
EISBN: 978-3-318-02416-6
... Abstract The combination of a proton pump inhibitor (PPI) with two of the following three antibiotics, amoxicillin, clarithromycin, and metronidazole, has been reported to achieve a high eradication rate. These regimens are accepted as standard regimens worldwide. The rationale of PPI-based...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350626
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. There are genetic differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into four...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350638
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are widely used for maintenance treatment of gastroesophageal reflux diseases as well as prevention of gastroduodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs. Since they are used for long periods concurrently with other drugs...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350635
EISBN: 978-3-318-02416-6
... Abstract Proton-pump inhibitors (PPIs) are some of the most widely used drugs in the world. Although the safety of PPIs is well established, there are several side effects, including some which have only recently been recognized. The side effects include diarrhea and various symptoms due...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350628
EISBN: 978-3-318-02416-6
... Abstract During the last two decades the therapeutic superiority of proton pump inhibitors (PPIs) over other drugs has dramatically changed the management of gastroesophageal reflux disease (GERD). Their important clinical efficiency as compared with previous drugs, especially H 2 -receptor...
Book Chapter
Series: Genome Dynamics
Volume: 3
Published: 13 September 2007
10.1159/000107601
EISBN: 978-3-8055-8341-1
... Abstract Protein-protein interactions (PPIs) are one of the most important components of biologicalnetworks. It is important to understand the evolutionary process of PPIs in order to elucidatehow the evolution of biological networks has contributed to diversification of the existentorganisms...
Book
Book Cover Image
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/isbn.978-3-318-02416-6
EISBN: 978-3-318-02416-6
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350632
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are effective in preventing recurrent peptic ulcer bleeding when used in high-dose intravenous infusion or oral form. Intermittent injection or low-dose administration of PPIs may not produce such benefit. These findings are based on meta-analysis...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350633
EISBN: 978-3-318-02416-6
... in individual response to stress exist in the background. Acid is considered to be a factor that modifies the manifestation of FD symptoms. Although it has not been proven that excessive gastric acid is present in FD patients, proton pump inhibitors (PPIs) are widely used as first-line drugs in the treatment...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350624
EISBN: 978-3-318-02416-6
... Abstract Omeprazole (OPZ), developed by AB Hässle/Astra (Sweden), and lansoprazole (LPZ), developed by Takeda Chemical Industries Ltd. (Japan), were the world's first and second proton pump inhibitors (PPIs), respectively, approved for clinical use in humans. These PPIs have been widely used...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350629
EISBN: 978-3-318-02416-6
... and complications. This review will focus on the use of proton pump inhibitors (PPIs) in the prevention and healing of NSAID-induced gastroduodenal lesions. The role of PPIs will be compared with alternative gastroprotective agents and placebo. Gastrointestinal (GI) adverse effects of nonsteroidal anti...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350634
EISBN: 978-3-318-02416-6
... Abstract The use of acid suppression in patients with exocrine pancreatic insufficiency (EPI) additionally to enteric-coated pancreatic enzyme preparations (PEPs) is controversial. In current recommendations, the prescription of proton pump inhibitors (PPIs) is not generally recommended...
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 101
Published: 21 May 2015
10.1159/000371703
EISBN: 978-3-318-02341-1
... finding in patients undergoing gastroscopy for other suspected conditions, including coeliac disease. EoE is different from gastro-oesophageal reflux disease and does not improve in response to proton pump inhibitors. Therefore, EoE needs to be distinguished from so-called PPI-responsive oesophageal...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 113
Published: 17 April 2015
10.1159/000360346
EISBN: 978-3-318-02691-7
... of GER medications (specifically proton pump inhibitors, PPI) and/or changing to elemental formulae [ 5 ] are encouraged and can be done simultaneously. Consultation with a pediatric gastroenterologist during the interstage period is ideal to ensure optimal titration of gastrointestinal medications...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 27
Published: 13 November 2009
10.1159/000258347
EISBN: 978-3-8055-9309-0
... aggregation (even disintegration), promoting clot lysis due to pepsin activating by acid, and further increasing the fibrinolytic activity that is impaired. Based on in vitro and animal data, a pH of 6-6.5 is targeted to reverse these effects and maintain clot stability. Proton pump inhibitors (PPI...
Book
Book Cover Image
Series: Genome Dynamics
Volume: 3
Published: 13 September 2007
10.1159/isbn.978-3-8055-8341-1
EISBN: 978-3-8055-8341-1
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 113
Published: 17 April 2015
10.1159/000360341
EISBN: 978-3-318-02691-7
.... In the case of infantile and childhood reflux, however, the history is neither sensitive nor specific enough to be credibly relied on for a diagnosis of GERD. This was demonstrated by Orenstein et al. [ 7 ], who attempted to treat infants with a history suggestive of GERD with proton pump inhibitors (PPI...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 27
Published: 13 November 2009
10.1159/000258356
EISBN: 978-3-8055-9309-0
... , 21 ]. Patients should use high-dose proton pump inhibitor (PPI) therapy twice daily beginning several days before PDT and for at least 3 months after the treatment. On the day of laser treatment, gastric pH can be checked. If the pH is 4 or less, the dose of PPI should be doubled and pH checked...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 30
Published: 22 June 2012
10.1159/000338427
EISBN: 978-3-318-02184-4
... patients taking proton pump inhibitors (PPIs), the situation is similar) there is increased esophageal mucosal permeability and DISs are seen, suggesting that the DISs might be involved in the development or persistence of symptoms [ 11 ]. DISs can be seen to resolve after with PPI therapy, but patients...